Published in JAMA Network Open · View the paper (DOI)
A modeling study finds that COVID-19 vaccination is more cost-effective for individuals aged 65 and above, with favorable results across different parameter input scenarios. The study's findings support the Advisory Committee on Immunization Practices' decision to recommend vaccination with the 2023-2024 mRNA vaccines.
Coverage from 2 institutions